Anticitrullinated-protein-antibody-positive individuals who progressed to RA exhibited a marked expansion of CXCR5+CD69+-activated naive B cells (aNAVs) before disease onset that displayed inflammatory and senescent-like transcriptional programs and expressed polyreactive, autoreactive IgM B cell receptors.
Key Findings
Results
ACPA-positive individuals who progressed to clinical RA showed a marked expansion of CXCR5+CD69+ activated naive B cells (aNAVs) prior to disease onset.
aNAVs were identified as a distinct B cell population defined by CXCR5 and CD69 co-expression within the naive B cell compartment.
The expansion was detectable in the preclinical phase before clinical RA diagnosis.
The finding was validated across multiple independent preclinical RA cohorts.
aNAVs were also detectable in RA synovial tissue, linking the circulating population to the site of joint inflammation.
Results
aNAVs from ACPA-positive progressors displayed inflammatory and senescent-like transcriptional programs.
Transcriptional profiling revealed gene expression signatures consistent with both inflammation and cellular senescence.
The senescent-like phenotype was described as distinct from classical B cell activation or differentiation states.
The senescent-like transcriptional program was validated across multiple independent preclinical RA cohorts.
This senescent-like programming distinguishes aNAVs from other naive B cell populations.
Results
aNAVs expressed polyreactive and autoreactive IgM B cell receptors.
B cell receptors on aNAVs were characterized as IgM isotype.
These receptors exhibited polyreactivity, meaning they could bind multiple antigens.
The receptors also demonstrated autoreactivity, consistent with a potential role in autoimmune pathogenesis.
This autoreactive BCR profile suggests aNAVs may have escaped or bypassed normal B cell tolerance checkpoints.
Results
In vitro stimulation of aNAVs with citrullinated antigens promoted T cell activation in a human leukocyte antigen (HLA)-dependent manner.
Experiments were conducted in vitro using citrullinated antigens to stimulate aNAVs.
T cell activation was observed as a downstream consequence of aNAV stimulation.
The T cell activation was HLA-dependent, implicating antigen presentation as the mechanistic link.
This finding supports a functional role for aNAVs in driving adaptive immune responses relevant to RA pathogenesis.
Results
Chronic exposure to citrullinated antigens and CpG synergistically drove activation and senescent-like programming in naive B cells from individuals with RA.
CpG is described as an innate immune stimulant, implicating toll-like receptor signaling in the process.
The combination of citrullinated antigens and CpG acted synergistically, not merely additively.
Naive B cells from RA individuals were used in these in vitro experiments.
This finding suggests a mechanism by which repeated antigen exposure combined with innate immune signals could generate aNAVs in vivo.
Conclusions
Senescent-like aNAVs were identified as potential contributors and therapeutic targets for RA prevention.
The authors frame aNAVs as relevant to the preclinical, at-risk stage of RA defined by ACPA positivity.
Their presence before clinical onset positions them as potential targets for preventive intervention.
The therapeutic target framing is based on both their expansion in progressors and their functional capacity to promote T cell activation.
The senescent-like nature of these cells may inform specific therapeutic strategies targeting senescence pathways.
What This Means
Rheumatoid arthritis (RA) is an autoimmune disease that attacks the joints. Scientists have known for years that certain blood proteins called anti-citrullinated protein antibodies (ACPAs) can appear in people years before they develop RA symptoms, but it has been unclear why only some of these 'at-risk' individuals go on to develop the disease. This research suggests that a specific type of immune cell — called activated naive B cells (aNAVs) — builds up in the blood of ACPA-positive people who later develop RA, and this buildup occurs before any clinical symptoms appear. These cells carry unusual features: they look like they are in a stressed, aging-like ('senescent') state, they produce antibodies that can mistakenly target the body's own tissues, and they can activate other immune cells (T cells) when exposed to proteins modified in a way seen in RA joints.
The study also found these abnormal B cells inside the joints of RA patients, and showed in laboratory experiments that exposing healthy naive B cells to citrullinated proteins (the kind targeted by ACPA) together with a bacterial-like immune trigger caused them to develop the same stressed, activated characteristics seen in aNAVs. This suggests that repeated exposure to these modified proteins, combined with signals that normally fight infection, may train certain B cells to become persistently activated and potentially harmful.
This research matters because it identifies a specific, measurable cell population that appears in the blood before RA develops, which could potentially serve as a biomarker to better predict who among ACPA-positive individuals will progress to clinical disease. Additionally, because these cells show a distinctive senescent-like state, they may represent a novel therapeutic target — meaning future treatments aimed at eliminating or reprogramming these cells could potentially prevent RA from developing in at-risk individuals, rather than only treating the disease after it begins.
Wu X, Zhang M, Moon J, Song E, Abrams J, van Dam L, et al.. (2026). Senescent-like activated naive B cells contribute to progression to clinical rheumatoid arthritis.. Nature aging. https://doi.org/10.1038/s43587-026-01236-6